REPRONEX
LOE ApproachingBLAINTRAMUSCULAR, SUBCUTANEOUSINJECTABLE
Approved
Aug 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
REPRONEX is a gonadotropin injection indicated for fertility treatment, administered via intramuscular or subcutaneous routes. The product is a biological therapeutic used in assisted reproductive technology protocols to stimulate ovarian follicle development in women undergoing fertility treatment.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), likely constraining team size and limiting growth opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
REPRONEX currently shows zero linked job openings, reflecting the mature lifecycle stage and approaching loss of exclusivity. Roles on this product are likely stable but declining, with limited growth trajectory and potential team restructuring.
Brand ManagerSales Representative
Worked on REPRONEX at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.